Mr Mike Rhodin, senior vice president, IBM Watson Group
Leading lifesciences organizations are deploying Watson Discovery Advisor to advance discoveries in ongoing research projects, including Baylor College of Medicine, Johnson and Johnson and The New York Genome Center.
Sanofi is exploring how working with Watson can speed up the discovery of alternate indications for existing drugs (drug re-purposing).
Watson is able to understand and extract key information by reading millions of pages of scientific literature and then visualizes relationships between drugs and other potential diseases they could target while providing supporting evidence each step of the way.
Drug safety and toxicity is a major driver of the high failure rate in clinical development and trials.
Sanofi is exploring how Watson's ability to understand, extract and organize toxicological information can enable researchers to make better informed decisions with respect to candidate progression.